JP5008812B2 - Et−743の抗腫瘍性類似体 - Google Patents

Et−743の抗腫瘍性類似体 Download PDF

Info

Publication number
JP5008812B2
JP5008812B2 JP2001584288A JP2001584288A JP5008812B2 JP 5008812 B2 JP5008812 B2 JP 5008812B2 JP 2001584288 A JP2001584288 A JP 2001584288A JP 2001584288 A JP2001584288 A JP 2001584288A JP 5008812 B2 JP5008812 B2 JP 5008812B2
Authority
JP
Japan
Prior art keywords
compound
mmol
alkyl
solution
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001584288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533532A (ja
JP2003533532A5 (enExample
Inventor
カルメン・クエヴァス
イグナシオ・マンサナーレス
マルタ・ペレス
マリア・ヘスス・マルティン
アルメルト・ロドリゲス
シモン・ムント
Original Assignee
ファルマ・マール・ソシエダード・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2000/001852 external-priority patent/WO2000069862A2/en
Application filed by ファルマ・マール・ソシエダード・アノニマ filed Critical ファルマ・マール・ソシエダード・アノニマ
Publication of JP2003533532A publication Critical patent/JP2003533532A/ja
Publication of JP2003533532A5 publication Critical patent/JP2003533532A5/ja
Application granted granted Critical
Publication of JP5008812B2 publication Critical patent/JP5008812B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2001584288A 2000-05-15 2001-05-15 Et−743の抗腫瘍性類似体 Expired - Lifetime JP5008812B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBPCT/GB00/01852 2000-05-15
GB00/01852 2000-05-15
PCT/GB2000/001852 WO2000069862A2 (en) 1999-05-14 2000-05-15 Hemisynthetic method and intermediates thereof
PCT/GB2001/002110 WO2001087894A1 (en) 1999-05-14 2001-05-15 Antitumoral analogs of et-743

Publications (3)

Publication Number Publication Date
JP2003533532A JP2003533532A (ja) 2003-11-11
JP2003533532A5 JP2003533532A5 (enExample) 2008-07-03
JP5008812B2 true JP5008812B2 (ja) 2012-08-22

Family

ID=29415238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001584288A Expired - Lifetime JP5008812B2 (ja) 2000-05-15 2001-05-15 Et−743の抗腫瘍性類似体

Country Status (9)

Country Link
US (3) US7247629B2 (enExample)
JP (1) JP5008812B2 (enExample)
AT (1) ATE282624T1 (enExample)
BG (1) BG65897B1 (enExample)
CA (1) CA2405002C (enExample)
HU (1) HU230699B1 (enExample)
IL (1) IL152126A (enExample)
MX (1) MXPA02011319A (enExample)
SK (1) SK287833B6 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100643092B1 (ko) * 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02010088A (es) * 2000-04-12 2004-08-19 Pharma Mar Sa Derivados de ecteinascidina antitumorales.
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
US20090325971A1 (en) * 2005-03-02 2009-12-31 The Trustees Of Columbia University In The City Of New York Pentacyclic Alkaloid Compounds and Methods of Use Thereof
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR20110028454A (ko) * 2008-05-16 2011-03-18 파르마 마르 에스.에이. 다발성 골수종 치료법
US20110070232A1 (en) * 2008-05-16 2011-03-24 Pharma Mar, S.A. Combination Therapy with an Antitumor Alkaloid
CN107033164A (zh) 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
SI2786753T1 (sl) 2010-11-12 2019-05-31 Pharma Mar S.A. Kombinacijska terapija s protitumorskim antibiotikom
GB2519773C (en) * 2013-10-29 2018-01-03 Solus Tech Limited Mode-locking semiconductor disk laser (SDL)
CN107522698B (zh) * 2016-06-20 2021-12-28 浙江海正药业股份有限公司 一种曲贝替定的制备方法及其中间体
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
JP7760183B2 (ja) * 2021-03-03 2025-10-27 国立大学法人 東京大学 マクロ環含有新規テトラヒドロイソキノリンアルカロイド化合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3774435D1 (de) 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
EP0309744A3 (de) * 1987-09-29 1989-06-28 Siemens Aktiengesellschaft Anordnung mit einem flächig sich erstreckenden Dünnfilmwellenleiter
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
ES2162235T3 (es) * 1996-01-15 2001-12-16 Janssen Pharmaceutica Nv Piridazinaminas inhibidoras de la angiogenesis.
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
EP1876180A3 (en) * 1998-04-06 2009-12-16 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
IL139472A0 (en) * 1998-05-05 2001-11-25 Ruffles Graham Keith Culture of sessile marine animals
KR100643092B1 (ko) * 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
CN1364321B (zh) * 1999-07-23 2010-06-02 美国超导体公司 多层制品及其制造方法
JP2003520801A (ja) * 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
US6815544B2 (en) * 2000-02-11 2004-11-09 President And Fellows Of Harvard College Synthetic process for an intermediate for ecteinascidin and phthalascidin compounds
US6569859B1 (en) * 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MXPA02010088A (es) 2000-04-12 2004-08-19 Pharma Mar Sa Derivados de ecteinascidina antitumorales.
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
JP2004506430A (ja) * 2000-08-11 2004-03-04 シティ・オブ・ホープ Sxrによるトランス活性化の抗新生物剤et−743による阻害
BR0115162A (pt) 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
EP1435988A4 (en) 2001-10-19 2008-01-09 Pharmamar Sa IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en) * 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー, ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
PL1827500T3 (pl) 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
AU2008313634A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
US20110070232A1 (en) 2008-05-16 2011-03-24 Pharma Mar, S.A. Combination Therapy with an Antitumor Alkaloid
KR20110028454A (ko) 2008-05-16 2011-03-18 파르마 마르 에스.에이. 다발성 골수종 치료법

Also Published As

Publication number Publication date
ATE282624T1 (de) 2004-12-15
SK287833B6 (sk) 2011-11-04
US7247629B2 (en) 2007-07-24
HK1053653A1 (en) 2003-10-31
JP2003533532A (ja) 2003-11-11
US20040019056A1 (en) 2004-01-29
HUP0302327A3 (en) 2006-05-29
SK16012002A3 (sk) 2003-05-02
US20060019960A1 (en) 2006-01-26
HUP0302327A2 (hu) 2003-10-28
BG107302A (bg) 2003-07-31
MXPA02011319A (es) 2003-06-06
US20080051407A1 (en) 2008-02-28
US8012975B2 (en) 2011-09-06
IL152126A0 (en) 2003-05-29
HU230699B1 (hu) 2017-09-28
US7410969B2 (en) 2008-08-12
CA2405002A1 (en) 2001-11-22
CA2405002C (en) 2010-09-21
BG65897B1 (bg) 2010-04-30
IL152126A (en) 2013-04-30

Similar Documents

Publication Publication Date Title
JP5008812B2 (ja) Et−743の抗腫瘍性類似体
CN100475822C (zh) 生产海鞘素化合物的合成方法
CN1436191B (zh) 抗肿瘤海鞘素衍生物
EP1496060B1 (en) Antitumoral analogs of ET-743
JP4942900B2 (ja) エクチナサイジン化合物の製造のための合成方法
BG106216A (bg) Полусинтетичен метод и нови съединения
HK1053653B (en) Antitumoral analogs of et-743

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120508

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120530

R150 Certificate of patent or registration of utility model

Ref document number: 5008812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150608

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term